These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1442 related articles for article (PubMed ID: 19031184)

  • 1. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.
    Yoshizako T; Wada A; Hayashi T; Uchida K; Sumura M; Uchida N; Kitagaki H; Igawa M
    Acta Radiol; 2008 Dec; 49(10):1207-13. PubMed ID: 19031184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transition zone prostate cancer: detection and localization with 3-T multiparametric MR imaging.
    Hoeks CM; Hambrock T; Yakar D; Hulsbergen-van de Kaa CA; Feuth T; Witjes JA; Fütterer JJ; Barentsz JO
    Radiology; 2013 Jan; 266(1):207-17. PubMed ID: 23143029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer detection with 3 T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging.
    Kitajima K; Kaji Y; Fukabori Y; Yoshida K; Suganuma N; Sugimura K
    J Magn Reson Imaging; 2010 Mar; 31(3):625-31. PubMed ID: 20187206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the potential of diffusion-weighted imaging in prostate cancer detection.
    Morgan VA; Kyriazi S; Ashley SE; DeSouza NM
    Acta Radiol; 2007 Jul; 48(6):695-703. PubMed ID: 17611881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of diffusion-weighted imaging for the prediction of prostate cancer location at 3T using a phased-array coil: preliminary results.
    Kim CK; Park BK; Lee HM; Kwon GY
    Invest Radiol; 2007 Dec; 42(12):842-7. PubMed ID: 18007156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Added value of breathhold diffusion-weighted MRI in detection of small hepatocellular carcinoma lesions compared with dynamic contrast-enhanced MRI alone using receiver operating characteristic curve analysis.
    Xu PJ; Yan FH; Wang JH; Lin J; Ji Y
    J Magn Reson Imaging; 2009 Feb; 29(2):341-9. PubMed ID: 19161186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of prostate DCE-MRI: comparison of fast exchange limit and fast exchange regimen pharmacokinetic models in the discrimination of malignant from normal tissue.
    Lowry M; Zelhof B; Liney GP; Gibbs P; Pickles MD; Turnbull LW
    Invest Radiol; 2009 Sep; 44(9):577-84. PubMed ID: 19668002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis--correlation with biopsy and histopathology.
    Kozlowski P; Chang SD; Jones EC; Berean KW; Chen H; Goldenberg SL
    J Magn Reson Imaging; 2006 Jul; 24(1):108-13. PubMed ID: 16767709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wash-in rate on the basis of dynamic contrast-enhanced MRI: usefulness for prostate cancer detection and localization.
    Kim JK; Hong SS; Choi YJ; Park SH; Ahn H; Kim CS; Cho KS
    J Magn Reson Imaging; 2005 Nov; 22(5):639-46. PubMed ID: 16200542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging.
    Tanimoto A; Nakashima J; Kohno H; Shinmoto H; Kuribayashi S
    J Magn Reson Imaging; 2007 Jan; 25(1):146-52. PubMed ID: 17139633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer detection with 3-T MRI: comparison of diffusion-weighted and T2-weighted imaging.
    Miao H; Fukatsu H; Ishigaki T
    Eur J Radiol; 2007 Feb; 61(2):297-302. PubMed ID: 17085002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Quantitative dynamic MRI and localisation of non-palpable prostate cancer].
    Cornud F; Beuvon F; Thévenin F; Chauveinc L; Vieillefond A; Descazeaux A; Flam T
    Prog Urol; 2009 Jun; 19(6):401-13. PubMed ID: 19467459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy.
    Haider MA; Chung P; Sweet J; Toi A; Jhaveri K; Ménard C; Warde P; Trachtenberg J; Lockwood G; Milosevic M
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):425-30. PubMed ID: 17881141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffusion-weighted imaging of the prostate at 3 T for differentiation of malignant and benign tissue in transition and peripheral zones: preliminary results.
    Kim CK; Park BK; Han JJ; Kang TW; Lee HM
    J Comput Assist Tomogr; 2007; 31(3):449-54. PubMed ID: 17538295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Description of magnetic resonance imaging-derived enhancement variables in pathologically confirmed prostate cancer and normal peripheral zone regions.
    Zelhof B; Lowry M; Rodrigues G; Kraus S; Turnbull L
    BJU Int; 2009 Sep; 104(5):621-7. PubMed ID: 19281464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings.
    Villers A; Puech P; Mouton D; Leroy X; Ballereau C; Lemaitre L
    J Urol; 2006 Dec; 176(6 Pt 1):2432-7. PubMed ID: 17085122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer detection: comparison of T2-weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the three techniques combined.
    Chen M; Dang HD; Wang JY; Zhou C; Li SY; Wang WC; Zhao WF; Yang ZH; Zhong CY; Li GZ
    Acta Radiol; 2008 Jun; 49(5):602-10. PubMed ID: 18568549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Principal component analysis of dynamic contrast enhanced MRI in human prostate cancer.
    Eyal E; Bloch BN; Rofsky NM; Furman-Haran E; Genega EM; Lenkinski RE; Degani H
    Invest Radiol; 2010 Apr; 45(4):174-81. PubMed ID: 20177391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Locally recurrent prostate cancer after high-dose-rate brachytherapy: the value of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging in localizing tumors.
    Tamada T; Sone T; Jo Y; Hiratsuka J; Higaki A; Higashi H; Ito K
    AJR Am J Roentgenol; 2011 Aug; 197(2):408-14. PubMed ID: 21785087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver.
    Xu PJ; Yan FH; Wang JH; Shan Y; Ji Y; Chen CZ
    J Comput Assist Tomogr; 2010 Jul; 34(4):506-12. PubMed ID: 20657216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 73.